Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 6:2:2398212818817494.
doi: 10.1177/2398212818817494. eCollection 2018 Jan-Dec.

Purine and purinergic receptors

Affiliations
Review

Purine and purinergic receptors

Geoffrey Burnstock. Brain Neurosci Adv. .

Abstract

Adenosine 5'-triphosphate acts as an extracellular signalling molecule (purinergic signalling), as well as an intracellular energy source. Adenosine 5'-triphosphate receptors have been cloned and characterised. P1 receptors are selective for adenosine, a breakdown product of adenosine 5'-triphosphate after degradation by ectonucleotidases. Four subtypes are recognised, A1, A2A, A2B and A3 receptors. P2 receptors are activated by purine and by pyrimidine nucleotides. P2X receptors are ligand-gated ion channel receptors (seven subunits (P2X1-7)), which form trimers as both homomultimers and heteromultimers. P2Y receptors are G protein-coupled receptors (eight subtypes (P2Y1/2/4/6/11/12/13/14)). There is both purinergic short-term signalling and long-term (trophic) signalling. The cloning of P2X-like receptors in primitive invertebrates suggests that adenosine 5'-triphosphate is an early evolutionary extracellular signalling molecule. Selective purinoceptor agonists and antagonists with therapeutic potential have been developed for a wide range of diseases, including thrombosis and stroke, dry eye, atherosclerosis, kidney failure, osteoporosis, bladder incontinence, colitis, neurodegenerative diseases and cancer.

Keywords: Adenosine 5′-triphosphate; P1 receptor; P2X receptor; P2Y receptor; adenosine.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
The architecture of the P2X4 receptor. Stereoview of the homotrimeric ΔzfP2X4 structure viewed parallel to the membrane. Each subunit is depicted in a different colour. N-acetylglucosamine (NAG) and glycosylated asparagine residues are shown in stick representation. The grey bars suggest the boundaries of the outer (out) and inner (in) leaflets of the membrane bilayer. Source: Reproduced from Kawate et al. (2009), with permission from the Nature Publishing Group.
Figure 2.
Figure 2.
(a) Dendrogram to show relatedness of 29 P2X receptor subunits. Full-length amino acid sequences were aligned with Clustal W using default parameters. The dendrogram was constructed with TreeView. h, human (Homo sapiens); r, rat (Rattus norvegicus); m, mouse (Mus musculus); gp, guinea pig (Cavia porcellus); c, chicken (Gallus gallus); zf, zebrafish (Danio rerio); bf, bullfrog (Rana catesbeiana); x, claw-toed frog (Xenopus laevis); f, fugu (Takifugu rubripes). The ellipses indicate the apparent clustering by relatedness into subfamilies. Source: Reproduced from North (2002), with permission from the American Physiological Society. (b) A phylogenetic tree (dendrogram) showing the relationships among the current members of the P2Y receptor family (human P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 receptors) and the human UDP-glucose receptor (here indicated as the P2Y14 receptor). The P2Y receptors can be divided into two subgroups shown with green and lilac backgrounds. Sequences were aligned using CLUSTALX and the tree was built using the TREEVIEW software. Source: Reproduced from Abbracchio et al. (2003), with permission from Elsevier.

References

    1. Abbracchio MP, Burnstock G. (1994) Purinoceptors: Are there families of P2X and P2Y purinoceptors? Pharmacology & Therapeutics 64(3): 445–475. - PubMed
    1. Abbracchio MP, Burnstock G. (1998) Purinergic signalling: Pathophysiological roles. Japanese Journal of Pharmacology 78(2): 113–145. - PubMed
    1. Abbracchio MP, Boeynaems J-M, Barnard EA, et al. (2003) Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends in Pharmacological Sciences 24(2): 52–55. - PMC - PubMed
    1. Abbracchio MP, Burnstock G, Boeynaems J-M, et al. (2006) International Union of Pharmacology: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews 58(3): 281–341. - PMC - PubMed
    1. Alves LA, da Silva JH, Ferreira DN, et al. (2014) Structural and molecular modeling features of P2X receptors. International Journal of Molecular Sciences 15(3): 4531–4549. - PMC - PubMed

LinkOut - more resources